Fast Market Research

Recent Study: Metastatic Breast Cancer - Pipeline Review, H2 2016

Fast Market Research announces the availability of the new Global Markets Direct report, "Metastatic Breast Cancer - Pipeline Review, H2 2016", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/14/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Breast Cancer (Oncology) pipeline landscape.

Metastatic breast cancer (also called Stage IV or Advanced) is a stage of breast cancer in which cancer cells break away from the tumor in the breast, spread to other parts of the body and keep growing. Symptoms of metastatic breast cancer includes severe, progressive pain, and, less commonly, pathological fracture, erythema over the affected bone, swelling, jaundice, elevated liver enzymes, abdominal pain, loss of appetite, nausea, and vomiting. Other symptoms include fatigue, malaise and weight loss. Treatment includes hormone therapy, chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Metastatic Breast Cancer - Pipeline Review, H2 2016

The Metastatic Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 33, 81, 52, 2, 52, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 7 and 1 molecules, respectively.Metastatic Breast Cancer.

Metastatic Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Metastatic Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Metastatic Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Metastatic Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Metastatic Breast Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Companies Mentioned in this Report: 3SBio Inc, AB Science SA, AbbVie Inc, Acceleron Pharma Inc, Acetylon Pharmaceuticals Inc, Adgero Biopharmaceuticals Inc, Advaxis Inc, Advenchen Laboratories LLC, Alteogen Inc, Amarna Therapeutics BV, Ambrx Inc, Amgen Inc, Aphios Corp, Arvinas Inc, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Bayer AG, Beta Pharma Inc, Biocon Ltd, Bionovis SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cantex Pharmaceuticals Inc, Cascadian Therapeutics Inc, CASI Pharmaceuticals Inc, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celltrion Inc, Clovis Oncology Inc, Corcept Therapeutics Inc, CSPC Pharmaceutical Group Limited, Curadis GmbH, Curaxys SL, Daiichi Sankyo Company Ltd, Deciphera Pharmaceuticals LLC, DexTech Medical AB, Dompe Farmaceutici SpA, Dr. Reddy's Laboratories Ltd, EirGenix Inc, Eisai Co Ltd, Eli Lilly and Company, Ensol Biosciences Inc, EOS Biosciences Inc, Epigen Biosciences Inc, Etubics Corp, F. Hoffmann-La Roche Ltd, FibroGen Inc, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genor BioPharma Co Ltd, Gilead Sciences Inc, Glycotope GmbH, GP Pharm SA, GTx Inc, Halozyme Therapeutics Inc, Hanmi Pharmaceuticals Co Ltd, Hetero Drugs Ltd, Humorigin Biotechnology Corp, Immune Design Corp, Immunomedics Inc, Immunophotonics Inc, Immupharma Plc, Incyte Corp, Intas Pharmaceuticals Ltd, Ionis Pharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Kadmon Corp LLC, Kancera AB, Karyopharm Therapeutics Inc, Laboratoires Pierre Fabre SA, Mabion SA, MacroGenics Inc, MandalMed Inc, Meabco A/S, MedImmune LLC, Medivation Inc, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, MetaStat Inc, Millennium Pharmaceuticals Inc, Morphotek Inc, Mycenax Biotech Inc, NantKwest Inc, Natco Pharma Ltd, Nektar Therapeutics, Neonc Technologies Inc, NewLink Genetics Corp, Nippon Kayaku Co Ltd, Northwest Biotherapeutics Inc, Novartis AG, Oasmia Pharmaceutical AB, OBI Pharma Inc, Oncobiologics Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Panacea Pharmaceuticals Inc, Paras Biopharmaceuticals Finland Oy, Pfizer Inc, Pharma Mar SA, PIQUR Therapeutics AG, Plexxikon Inc, Polaris Pharmaceuticals Inc, Polyphor Ltd, Prescient Therapeutics Ltd, Prima BioMed Ltd, Puma Biotechnology Inc, Radius Health Inc, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Seattle Genetics Inc, Shanghai Henlius Biotech Co Ltd, Sorrento Therapeutics Inc, Starpharma Holdings Ltd, Sun Pharma Advanced Research Company Ltd, SynCore Biotechnology Co Ltd, Syndax Pharmaceuticals Inc, Synthon Holdings BV, Taiho Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Ltd, Tocagen Inc, Transgene Biotek Ltd, Tyme Technologies Inc, Vaxil Bio Therapeutics Ltd, Vertex Pharmaceuticals Inc, VioQuest Pharmaceuticals Inc, Vyriad Inc, Wilex AG, WntResearch AB, ZIOPHARM Oncology Inc, Zymeworks Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Metastatic Breast Cancer - Pipeline Review, H1 2016
-Metastatic Colorectal Cancer - Pipeline Review, H2 2016
-Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016
-Breast Cancer - Pipeline Review, H2 2016
-Metastatic Pancreatic Cancer - Pipeline Review, H2 2016